Mark V. Roeder

Silicon Valley
  • 140 Scott Drive
  • Menlo Park, CA 94025
  • USA
Profile Experience

Mark Roeder represents life sciences and technology companies at all stages of their lifecycle, as well as the institutions that finance them. He serves as Global Co-Chair of the Life Sciences Industry Group and previously served as Co-Chair of the Silicon Valley Corporate Department.

Mr. Roeder advises companies on strategic transactions and corporate governance matters. Specifically, he counsels clients on:

  • Initial Public Offerings (IPOs)
  • Secondary and follow-on equity public offerings
  • Strategic buy-side and sell-side mergers and acquisitions
  • Venture capital financings
  • Convertible debt offerings

He also provides general company representation, advising executives and boards on topics such as:

  • Corporate governance matters
  • Fiduciary duties
  • Securities law compliance
  • Executive compensation matters
  • Shareholder activism and defense

Mr. Roeder frequently speaks on the IPO process and corporate governance matters.

Mr. Roeder's representative transactions include:

Life Sciences IPOs and Follow-on Equity Offerings – Company Representation
  • Ardelyx – US$60 million IPO and several follow-on equity offerings raising nearly US$350 million
  • Ascendis Pharma – US$124 million IPO and several follow-on equity public offerings raising more than US$900 million
  • CytomX Therapeutics – US$142 million follow-on equity public offering
  • Intermune –convertible notes offerings raising US$276 million, and several follow-on equity public offerings US$860 million
  • KYTHERA Biopharmaceuticals – US$80 million IPO and US$133 million follow-on offering
  • Mirna Therapeutics – US$49 million IPO
  • OncoMed Pharmaceuticals – US$87 million IPO  and US$51 million follow-on equity public offering
  • Relypsa – US$78 million IPO and multiple follow-on equity public offerings raising nearly US$300 million
  • UNITY Biotechnology – US$85 million IPO
Life Sciences IPOs and Follow-on Equity Offerings – Underwriters Representation
  • Aduro Biotech – US$136 million IPO
  • Alios BioPharma – US$1.75 billion sale to Johnson & Johnson
  • AveXis – several follow-on equity public offerings raising nearly US$750 million
  • CytomX Therapeutics – US$92 million IPO
Life Sciences – M&A Transactions
  • CV Therapeutics – US$1.5 billion sale to Gilead Sciences following a successful defense against a hostile bid by Astellas Pharma
  • DVS Sciences – US$208 million sale to Fluidigm
  • Envoy Therapeutics – US$140 million sale to Takeda Pharmaceutical
  • KYTHERA Biopharmaceuticals – US$2.1 billion sale to Allergan
  • Menlo Therapeutics – US$120 million IPO
  • Modernizing Medicines – US$58 million acquisition of gMed
  • Odonate Therapeutics – US$160 million initial public
  • Pearl Therapeutics – US$1.15 billion sale to AstraZeneca
  • Relypsa – US$1.53 billion sale to Galenica Group
Technology IPOs and Follow-on Offerings – Company Representation
  • Integrated Device Technology – US$374 million convertible notes offering
  • Mellanox Technologies – US$117 million IPO and follow-on public equity offering raising nearly US$100 million
Technology – M&A Transactions
  • Greenplum – sale to EMC (confidential terms)
  • Integrated Device Technology – US$1.7 billion merger with Integrated Circuit Systems
  • Integrated Device Technology – US$7.1 billion sale to Reneasas
  • Mellanox Technologies – US$6.9 billion sale to Nvidia, US$811 million purchase of EZ Chip, US$82 million purchase of Kotura, US$218 million purchase of Voltaire, and US$48 million purchase of IPtronics
  • Netli – US$170 million sale to Akamai Technologies
Venture Financings
  • Lead Investors’ counsel in hundreds of venture financings, including investments in: Carta,, Lucid Software, Duo Security, Mulesoft, Verkada, Cloudera, ROBLOX, Zulily, Tableau Software, and Box

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.